These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 16603535)
41. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. Baraz L; Friedler A; Blumenzweig I; Nussinuv O; Chen N; Steinitz M; Gilon C; Kotler M FEBS Lett; 1998 Dec; 441(3):419-26. PubMed ID: 9891983 [TBL] [Abstract][Full Text] [Related]
42. Expression and purification of active form of HIV-1 protease from E.coli. Wan M; Loh BN Biochem Mol Biol Int; 1995 Apr; 35(4):899-912. PubMed ID: 7627139 [TBL] [Abstract][Full Text] [Related]
43. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. Kotler M; Simm M; Zhao YS; Sova P; Chao W; Ohnona SF; Roller R; Krachmarov C; Potash MJ; Volsky DJ J Virol; 1997 Aug; 71(8):5774-81. PubMed ID: 9223465 [TBL] [Abstract][Full Text] [Related]
44. HIV-1 protease with leucine zipper fused at N-terminus exhibits enhanced linker amino acid-dependent activity. Yu FH; Wang CT Retrovirology; 2018 Apr; 15(1):32. PubMed ID: 29655366 [TBL] [Abstract][Full Text] [Related]
45. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518 [TBL] [Abstract][Full Text] [Related]
47. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. Partaledis JA; Yamaguchi K; Tisdale M; Blair EE; Falcione C; Maschera B; Myers RE; Pazhanisamy S; Futer O; Cullinan AB J Virol; 1995 Sep; 69(9):5228-35. PubMed ID: 7636964 [TBL] [Abstract][Full Text] [Related]
48. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. Resch W; Ziermann R; Parkin N; Gamarnik A; Swanstrom R J Virol; 2002 Sep; 76(17):8659-66. PubMed ID: 12163585 [TBL] [Abstract][Full Text] [Related]
49. HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected cells. Pettit SC; Sanchez R; Smith T; Wehbie R; Derse D; Swanstrom R AIDS Res Hum Retroviruses; 1998 Jul; 14(11):1007-14. PubMed ID: 9686647 [TBL] [Abstract][Full Text] [Related]
50. An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity. Konvalinka J; Litterst MA; Welker R; Kottler H; Rippmann F; Heuser AM; Kräusslich HG J Virol; 1995 Nov; 69(11):7180-6. PubMed ID: 7474139 [TBL] [Abstract][Full Text] [Related]
51. Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity. Tessmer U; Kräusslich HG J Virol; 1998 Apr; 72(4):3459-63. PubMed ID: 9525682 [TBL] [Abstract][Full Text] [Related]
52. Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. Leigh Brown AJ; Frost SD; Good B; Daar ES; Simon V; Markowitz M; Collier AC; Connick E; Conway B; Margolick JB; Routy JP; Corbeil J; Hellmann NS; Richman DD; Little SJ J Virol; 2004 Mar; 78(5):2242-6. PubMed ID: 14963120 [TBL] [Abstract][Full Text] [Related]
53. Association of murine leukemia virus pol with virions, independent of Gag-Pol expression. Buchschacher GL; Yu L; Murai F; Friedmann T; Miyanohara A J Virol; 1999 Nov; 73(11):9632-7. PubMed ID: 10516075 [TBL] [Abstract][Full Text] [Related]
54. Effects of human immunodeficiency virus type 1 transframe protein p6* mutations on viral protease-mediated Gag processing. Chiu HC; Wang FD; Chen YA; Wang CT J Gen Virol; 2006 Jul; 87(Pt 7):2041-2046. PubMed ID: 16760407 [TBL] [Abstract][Full Text] [Related]
55. A folding inhibitor of the HIV-1 protease. Broglia RA; Provasi D; Vasile F; Ottolina G; Longhi R; Tiana G Proteins; 2006 Mar; 62(4):928-33. PubMed ID: 16385559 [TBL] [Abstract][Full Text] [Related]
56. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors. Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409 [TBL] [Abstract][Full Text] [Related]
60. Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. Davis DA; Yusa K; Gillim LA; Newcomb FM; Mitsuya H; Yarchoan R J Virol; 1999 Feb; 73(2):1156-64. PubMed ID: 9882317 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]